LFCR
Lifecore Biomedical Inc.
4.20$
-2.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
Lifecore Biomedical Inc. (LFCR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2026), "Revenue" came in at 129 million $. Tick rows to compare them in a chart.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.5 | 9.5 | 34 | 35 | 210 | 191 | 183 | 192 | 205 | 232 | 210 | 239 | 236 | 238 | 277 | 318 | 442 | 477 | 539 | 541 | 532 | 524 | 558 | 160 | 101 | 186 | 111 | 128 | 129 | 129 | |
| 0.5 | 5.1 | 18 | 19 | 170 | 163 | 152 | 162 | 173 | 192 | 178 | 200 | 202 | 204 | 230 | 265 | 379 | 414 | 474 | 470 | 449 | 446 | 477 | 121 | 62 | 135 | 72 | 86 | 89 | 89 | |
| 2.0 | 4.4 | 15 | 16 | 39 | 28 | 31 | 30 | 32 | 40 | 32 | 38 | 34 | 34 | 47 | 52 | 63 | 63 | 65 | 71 | 83 | 78 | 81 | 39 | 39 | 50 | 39 | 42 | 40 | 41 | |
| 3.8 | 7.6 | 5.7 | 5.8 | 4.7 | 3.3 | 3.7 | 3.7 | 2.5 | 3.0 | 3.1 | 3.3 | 3.7 | 4.4 | 9.3 | 9.6 | 9.3 | 7.2 | 7.0 | 7.2 | 9.5 | 13 | 11 | 7.6 | 6.7 | 7.8 | 7.8 | 8.6 | 8.3 | 8.5 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 35 | – | 47 | 56 | 51 | 63 | 72 | 65 | 46 | 42 | 43 | 44 | – | |
| 7.6 | 13 | 19 | 19 | 40 | 30 | 30 | 26 | 26 | 31 | 2.0 | 23 | 22 | 22 | 34 | 36 | 38 | 42 | 47 | 57 | 68 | 65 | 76 | 65 | 48 | 54 | 51 | 51 | 58 | 42 | |
| -5.6 | -9.0 | -3.3 | -3.1 | -0.2 | -2.6 | 1.3 | 4.1 | 6.0 | 9.0 | 30 | 15 | 13 | 12 | 8.0 | 15 | 25 | 20 | 18 | -20 | 16 | 12 | -8.0 | -26 | -8.8 | -3.6 | -12 | -8.8 | -17 | -1.3 | |
| 1.5 | 1.7 | 1.3 | 0.4 | 4.3 | 2.2 | – | 0.0 | 0.0 | 0.0 | 24 | 1.7 | 0.0 | 0.1 | 0.8 | 0.9 | 2.0 | 1.7 | 1.8 | 2.0 | 1.8 | 2.0 | 5.2 | 4.6 | 8.9 | 17 | 16 | 18 | 22 | 2.2 | |
| -4.1 | -7.3 | -2.7 | -2.7 | -2.1 | -4.8 | 0.2 | 4.1 | 6.0 | 9.0 | 32 | 17 | 13 | 8.7 | 8.4 | 20 | 32 | 30 | 21 | -19 | 15 | 16 | 3.6 | -31 | -30 | -52 | -21 | 9.5 | -39 | -30 | |
| -1.4 | -2.1 | 0.2 | 0.1 | 0.0 | 16 | 2.7 | 1.1 | 0.6 | 0.4 | 2.5 | 3.4 | 5.6 | 4.3 | 4.2 | 7.2 | 9.5 | 11 | 7.7 | -7.4 | 4.3 | -9.4 | 1.5 | -8.8 | -6.4 | -5.8 | -5.2 | 0.2 | 0.0 | 0.6 | |
| -4.2 | -8.6 | -2.9 | -2.8 | -4.0 | -19 | -1.5 | 2.9 | 5.4 | 8.7 | 29 | 14 | 7.7 | 4.0 | 3.9 | 13 | 23 | 19 | 14 | -12 | 11 | 25 | 2.1 | -38 | -32 | -97 | -117 | 12 | -39 | -31 | |
| -3.8 | -7.9 | -1.2 | -2.3 | 4.3 | 2.8 | 4.8 | 7.8 | 9.5 | 12 | 34 | 18 | 17 | 12 | 15 | 27 | 42 | 39 | 30 | -7.8 | 27 | 25 | 23 | -7.2 | -1.0 | -68 | 13 | 36 | -8.8 | 8.2 |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.